Humana and Boehringer Ingelheim Establish Partnership to Promote Population Health

Mon Mar 25, 2013 10:30am EDT

* Reuters is not responsible for the content in this press release.

New collaboration will focus on chronic diseases
LOUISVILLE, Ky. & RIDGEFIELD, Conn.--(Business Wire)--
Humana Inc. (NYSE: HUM), one of the nation`s leading health and well-being
companies, and Boehringer Ingelheim Pharmaceuticals, Inc., a research-based,
global pharmaceutical company, today announced a multi-year collaboration
dedicated to improving health care and reducing costs for people affected by
chronic obstructive pulmonary disease (COPD), cardiovascular disease, and other
chronic disease states. 

The partnership will leverage the strategic strengths of both organizations to
promote population health, initially focusing on the early identification of
COPD and other chronic diseases. Humana and Boehringer Ingelheim will bring
their combined health care and research expertise together with the goal of
enhancing patient health while reducing overall health care costs. 

"This strategic partnership will allow us to develop a better understanding of
how to improve the quality of care and better serve the immediate and long term
needs of our health care population," said William Fleming, Pharm.D., President
of Humana Pharmacy Solutions. "It is our hope that this collaboration will
ultimately create solutions and produce data that will better inform the
diagnosis, understanding and application of therapeutic interventions used to
improve the health of people affected by COPD and cardiovascular disease, as
well as other targeted chronic diseases." 

"We believe that the combination of Humana`s experience and Boehringer
Ingelheim`s commitment to delivering more health with a focus on driving
advancements in chronic conditions, including COPD and cardiovascular disease,
will help improve the health of the populations we serve," said Jeff Huth,
Senior Vice President, Managed Markets, Boehringer Ingelheim Pharmaceuticals,
Inc. "Through this important collaboration, we will harness the expertise of
both organizations to identify and further develop ways to improve health care
delivery and health outcomes for patients." 

Chronic diseases take a toll on population health. The American Lung Association
reports that more than 12 million Americans are living with COPD, as well as an
estimated 12 million more undiagnosed cases. According to the Centers for
Disease Control and Prevention, half of all Americans meet at least one of the
key risk factors for cardiovascular disease: high blood pressure, high LDL
cholesterol, or smoking. 

About Humana

Humana Inc., headquartered in Louisville, Ky., is a leading health care company
that offers a wide range of insurance products and health and wellness services
that incorporate an integrated approach to lifelong well-being. By leveraging
the strengths of its core businesses, Humana believes it can better explore
opportunities for existing and emerging adjacencies in health care that can
further enhance wellness opportunities for the millions of people across the
nation with whom the company has relationships. 

More information regarding Humana is available to investors via the Investor
Relations page of the company`s web site at, including copies

* Annual reports to stockholders 
* Securities and Exchange Commission filings 
* Most recent investor conference presentations 
* Quarterly earnings news releases 
* Replays of most recent earnings release conference calls 
* Calendar of events (including upcoming earnings conference call dates and
times, as well as planned interaction with research analysts and institutional
* Corporate Governance information

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the
largest U.S. Subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and
a member of the Boehringer Ingelheim group of companies. 

The Boehringer Ingelheim group is one of the world`s 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 145
affiliates and more than 44,000 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine. Our focus is primarily in the therapeutic areas
of cardiovascular disease, respiratory diseases, diseases of the central nervous
system, metabolic diseases, virological diseases and oncology. 

As a central element of its culture, Boehringer Ingelheim pledges to act in a
socially responsible manner. Involvement in social projects, caring for
employees and their families, and providing equal opportunities for all
employees form the foundation of the global operations. Mutual cooperation and
respect, as well as environmental protection and sustainability are intrinsic
factors in all of Boehringer Ingelheim`s endeavors.

Humana Corporate Communications
Alex Kepnes, 502-580-2990
Boehringer Ingelheim
Jennifer Forsyth, 203-791-5889

Copyright Business Wire 2013